作者: Oana Draghiciu , Joyce Lubbers , Hans W Nijman , Toos Daemen
DOI: 10.4161/21624011.2014.954829
关键词: Myeloid-derived Suppressor Cell 、 Blockade 、 Cancer 、 Gemcitabine 、 Immunology 、 Biology 、 Suppressor 、 Immunotherapy 、 In vivo 、 Cytotoxic T cell
摘要: Myeloid-derived suppressor cells (MDSCs) contribute to tumor-mediated immune escape and negatively correlate with overall survival of cancer patients. Nowadays, a variety methods target MDSCs are being investigated. Based on the intervention stage MDSCs, namely development, expansion activation, function turnover, these can be divided into: (I) prevention or differentiation mature cells, (II) blockade MDSC (III) inhibition suppressive activity (IV) depletion intratumoral MDSCs. This review describes effective mono- multimodal-therapies that for benefit treatment.